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INTRODUCTION
Renal cell carcinoma (RCC) accounts
for 2–3% of all adult malignancies world-
wide with increasing incidences. Up to
30% of RCC patients have metastases at
the time of diagnosis, and metastases de-
velop metachronously in 20–40% of pa-
tients undergoing partial or radical
nephrectomy. Metastatic renal cell carci-
noma (mRCC) is resistant to both con-
ventional chemotherapy and radiother-
apy. The response rate is very low, and
the 5-year survival of patients with
mRCC is <10%. Historically, a cytokine-
based immunotherapy with interleukin
(IL)-2 and interferon (IFN)-α was the
only therapeutic option for mRCC, with
response rates up to 20% and a median
survival of 5–25 months, depending on
drug combination and patient selection.
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Over the last decade, the development
of targeted molecular therapies as both
first- and second-line treatments has sub-
stantially improved the prognosis for pa-
tients with mRCC. These molecular
agents are mostly directed against signal-
ing pathways that foster angiogenesis.
They include receptor tyrosine kinase
 inhibitors (for example, sunitinib,
 sorafenib, pazopanib, axitinib, cediranib
and tivozanib), monoclonal antibodies
(for example, bevacizumab) and mam-
malian target of rapamycin (mTOR) in-
hibitors (for example, temsirolimus and
everolimus). Although some tumors
show regression, most patients develop
therapy resistance over time. Interest-
ingly, some molecular therapies may en-
hance antitumor responses; therefore,
immunotherapy in combination with ty-
rosine kinase inhibitors has become a re-
cent research focus (1–3).
Among cancer patients with solid tu-
mors, individuals with mRCC showed
some of the most favorable responses to
immunotherapy (4). Tumor cell vaccines
are of special interest, and there is evi-
dence that immunization against tumors
can reduce or even eliminate some lesions
and induce long-lasting T-cell memory re-
sponses, with a capacity to control tumor
relapse. One approach is to use autolo-
gous tumor cells, either alone or com-
bined with adjuvants, often after intro-
duction of immunologically relevant
genes to enhance tumor cell immuno-
genicity. The first phase I trial in RCC im-
plementing this strategy, by expressing
the gene encoding granulocyte-macro-
phage colony stimulating factor (GM-
CSF) in autologous tumor cells, demon-
strated induction of specific T-cell
immunity and clinical benefit (5,6). An au-
tologous gene-modified tumor cell vac-
cine expressing the costimulatory mole-
cule CD80 was tested in patients with
mRCC in combination with systemic IL-2
(7). Even fusion vaccines of autologous
tumor cells and allogeneic dendritic cells
(DCs) induced immune responses in a
significant number of patients (8,9). Se-
vere toxicities were not seen; however,
strong limitations in feasibility and high
costs were incurred with the production
of individualized vaccines. Generic tumor
cell vaccines that could be applied to
many patients would reduce production
costs, thereby enabling treatment of more
patients. Our previously reported clinical
trial used an allogeneic gene–modified
RCC tumor cell vaccine that acquired im-
proved immunogenicity through coex-
pression of CD80 and IL-2 (10). Vaccina-
tion was well tolerated, and substantial
disease stabilization was observed in
most patients. Preliminary immune moni-
toring demonstrated vaccine-induced re-
sponses against tumor lysates and a small
set of tumor-associated antigens (TAAs)
in the majority of the patients.
Here we report extended immune mon-
itoring of these study patients, including
assessment of enzyme-linked immunosor-
bent spot (ELISPOT) reactivity against nu-
merous new RCC-associated antigens,
and analyses of cytokines/ chemokines in
serum and culture supernatants of skin
biopsies taken from vaccine challenge
sites. Immune suppression in cancer pa-
tients often result from high numbers of
immune suppressor cell populations, in-
cluding natural regulatory T cells (nTregs)
and myeloid-derived suppressor cells
(MDSCs). For this reason, we also deter-




Fifteen patients with histologically
proven clear-cell RCC and at least one
evaluable metastasis were enrolled in the
clinical trial (10). Immune monitoring
was done for 12 patients. The study is
registered with the German Somatic
Gene Transfer Clinical Trial Database
(DeReG, reference number 47) and the
German Clinical Trial Register, partner
register of the World Health Organiza-
tion primary register (reference number
DRKS00000249). Only patients with an
HLA-A*02:01 allotype were included,
matching one major histocompatibility
complex class I molecule with the vac-
cine. Patients gave written informed con-
sent before the study. The clinical proto-
col was approved by the Ethics Com -
mittee of the Ludwig Maximilians Uni-
versity Munich, and good manufacturing
practice (GMP)-certified vaccine produc-
tion was approved by local, state and na-
tional authorities.
Vaccination and Study Schedule
The vaccine cell line RCC-26/ CD80/
IL-2 was generated as described previ-
ously (11). Vaccine cells were thawed im-
mediately before intradermal injection
into the inguinal region. Graded doses of
cells were applied up to 10 times over a
22-wk period (Supplementary Fig ure S1).
Clinical examination and routine blood
checks were performed at every visit. Pa-
tients were withdrawn from the study if
evidence of tumor progression appeared
according to RECIST criteria (response
evaluation criteria in solid tumors). In
four patients (MR-6, MR-7, MR-8 and
MR-9), the lowest vaccine dose (2.5 × 106
cells) was omitted and vaccination was
initiated with a dose of 1 × 107 cells.
Enzyme-linked Immunosorbent Spot
(ELISPOT)
Patient blood samples for ELISPOT
were obtained at wks 1, 6, 14, 22 and 36
(see Supplementary Figure S1), and
 peripheral blood mononuclear cells
(PBMCs) were isolated and cryopre-
served. Additional samples from five pa-
tients were taken on d 15 after the tenth
vaccination, and samples were available
from two patients during longer follow-
up. The IFN-γ ELISPOT assay was per-
formed as described (10). PBMCs were di-
rectly stimulated with selected peptides
(each peptide, 5 μg/mL) in serum-free
medium (CTL Test medium; Cellular
Technology Europe, Bonn, Germany),
supplemented with anti-CD28 antibody 
(1 μg/mL; BD Biosciences, San Jose, CA,
USA) and recombinant IL-2 (Proleukin,
2 U/mL; Chiron, Emeryville, CA, USA).
Spots were counted with the AID reader
system ELR03 with software versions 4.0
and 5.0 (Autoimmun Diagnostika [AID],
Strassberg, Germany) and controlled by
human audit. The mean spot number of
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quadruplicates for a given peptide had to
be at least two-fold over the mean back-
ground spot number. A response was con-
sidered to be vaccine induced, if the ratio
of peptide mean to background mean for
a given vaccination time point was at
least two-fold over the corresponding pre-
vaccination ratio. Surrogate peptides for
immune monitoring were selected from
sequences of TAAs shown to be overex-
pressed in metastatic RCC lesions and/or
the vaccine cells, by using HLA-A*02:01
motif-based epitope predictions available
on the web (http:// www.syfpeithi.de), or
as published in the literature. Several pep-
tides were identified by elution from the
RCC-26 cell line. Peptide sequences are
given in the supplementary Material and
Methods section ELISPOT.
Flow Cytometry
Surface immunostaining used directly
labeled monoclonal antibodies (mAbs)
from BD Biosciences: CD3, CD4, CD8,
CD25, CD39, CD127, CD11b, CD15,
CD14, CD33, CD124, HLA-DR and
CD19. The FoxP3 mAbs (eBiosciences,
Frankfurt, Germany) was used for nTreg
analysis. The LIVE/DEAD® Fixable Blue
Dead Cell Stain Kit, for UV excitation
(Molecular Probes®; Life Technologies,
Carlsbad, CA, USA) was applied for dis-
crimination of live/dead cells.
Flow cytometry was performed as de-
scribed in detail in the supplementary
Material and Methods section Flow Cy-
tometry. Briefly, isolated PBMCs were in-
cubated first with the LIVE/DEAD Fix-
able Blue dye, washed and stained with
directly labeled mAbs. Fix/Perm buffer
(eBiosciences) was used for intracellular
staining with FoxP3 antibody. Cells were
analyzed by using an  LSRII (BD Bio-
sciences). Data were processed by using
FlowJo software (version 8.8.6; Tree Star,
Ashland, OR, USA).
Cytokine/Chemokine Assays
Commercial ELISA kits and protocols
(R&D Systems, Wiesbaden, Germany)
were used for vascular endothelial
growth factor (VEGF), VEGF-C, VEGF-D,
transforming growth factor (TGF)-β1 and
prostaglandin E2 (PGE2). For all other
 cytokines (IL-1β, IL-2, IL-4, IL-5, IL-6,
IL-10, IL-12p70, IL-13, IL-17, tumor
necrosis factor [TNF]-α, IFN-γ, GM-CSF,
G-CSF) and chemokines (CXCL8 [IL-8],
CXCL9 [monokine induced by gamma-
interferon {MIG}], CXCL10 [IP-10], CCL2
[monocyte chemotactic protein-1 {MCP-
1}], CCL4 [macrophage inflammatory
protein-1β {MIP-1β}] and CCL5 [regu-
lated upon activation normal T cell ex-
pressed and presumably secreted
{RANTES}]), the Luminex (BioPlex; Bio-
Rad, Munich, Germany) and the multi-
plex cytokine bead array systems from
BD Biosciences (CBA kit for chemokines
and CBA Flex Set) were used according
to the manufacturers’  instructions.
Serum samples were obtained before
and after the first, fourth, fifth, eighth,
ninth and tenth vaccinations (see Supple-
mentary Figure S1). Prevaccination
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Table 1. Patient characteristics, vaccination course and clinical outcome.
Prognostic Therapy before Site(s) of 2.5 × 106 10 × 106 40 × 106 Site(s) of TTP Survival 
ID scorea study entry metastases cells cells cells progression (wks) (wks)
MR-1 2 — Lung, bone 4 1 — Bone, brainb 7 31
MR-2 1 Cytokine,c G250d Lung, LN 4 4 2 Pleura,b boneb 23 79
MR-4 1 Cytokine, G250 Lung, LN, adrenal 4 4 2 Lung 35 68
gland
MR-5 1 Cytokine Lung 4 4 2 LN,b adrenal glandb 7 76
MR-6 2 — Bone — 4 2 Bone 6 18
MR-7 1 — LN, pleura, local — 4 2 Pleura, liverb 28 84
recurrence
MR-9 2 Cytokine Lung, pancreas — 4 2 Pancreas, liverb 39 79
MR-10 0 Sorafenib Lung 4 4 2 Brainb 23 55
MR-11 2 G250 Lung, LN, spinal cord 4 4 — — SD (7)e 17f
MR-13 1 DC, multi-peptide Lung, LN, brain 4 4 2 Brain 33 104
vaccine
MR-14 2 Multi-peptide Lung, LN, adrenal 4 4 2 LN 35 107
vaccine gland
MR-15 1 Cytokine Lung, LN 4 4 2 — SD (131)e 151 (alive)
TTP, time to progression; LN, lymph node; DC, dendritic cell; SD, stable disease.
aPalmer score from 0 (very low risk) to 3 (high risk) based on performance status, number of metastatic sites and the time from first
diagnosis to study entry (14).
bNew metastases.
cCytokine: IFN-α, IL-2, 5-fluorouracil.
dG250: monoclonal antibody directed against carbonic anhydrase IX.
eSD (7) and SD (131) indicate stable disease at wks 7 and 131, respectively.
fDeath of patient MR-11, not related to therapy or disease.
PBMCs (wk 1) and PBMCs from wk 22
were cultured with parental RCC-26 cells
and with RCC-26/CD80/IL-2 vaccine
cells. Skin-infiltrating lymphocytes
grown from biopsies (wks 6, 14 and 22)
for 10–19 d were measured for cytokine/
chemokine secretion at 24–48 h after
stimulation with RCC-26 and vaccine
cells. The FACSCalibur was used for the
CBA assays. The Luminex 100 Reader
was used for the BioPlex assays. Details
for sample processing, culturing and
analysis are described in the supplemen-
tary Material and Methods section
 Cytokine/Chemokine Assays.
Analysis of the Demethylation of the
Foxp3 Gene
Genomic DNA was isolated by using
the DNeasy blood and tissue kit (Qiagen,
Hilden, Germany). Bisulphite treatment
of genomic DNA was performed as de-
scribed (12) with minor modifications. A
quantitative real-time (qRT) polymerase
chain reaction (PCR)-based methylation
assay with methylation- and demethyla-
tion-specific amplification primers was
used to analyze the Foxp3 Treg-specific
demethylated region DNA, as described
(13). Samples were analyzed in triplicate
by using a LightCycler 480 System
(Roche, Mannheim, Germany). Cycling
conditions and data analysis are de-
scribed in the supplementary Material
and Methods section Analysis of the
Demethylation of the Foxp3 Gene.
Microarray Analysis
Tissue samples from 32 patients with
clear-cell RCC metastases were collected,
snap-frozen and stored in liquid nitrogen
after written informed consent was ob-
tained. The study was approved by the
ethics committee of the Ludwig Maximil-
ians University Munich. Cryostat sec-
tions were made, and laser microdissec-
tion was used to isolate tumor cells
(PALM MicroBeam; Zeiss, Munich, Ger-
many). Processing of the probes is de-
scribed in detail in the supplementary
Material and Methods section Microar-
ray Analysis.
All supplementary materials are available
online at www.molmed.org.
RESULTS
Study Patients Had Advanced Disease
Characteristics of study patients, indi-
vidual vaccination courses and some
clinical parameters are summarized in
Table 1 and Supplementary Table S1.
Study details were described previously
(10). More than half of the patients had
poor prognosis scores (>0) according to
Palmer et al. (14), revealing their ad-
vanced states of disease. All patients
had good performance status (Eastern
Cooperative Oncology Group scores of
0 or 1; data not shown). Of the 12 pa-
tients evaluated here, 8 were treated be-
fore study entry with other im-
munotherapies, with the majority
receiving subcutaneous IFN-α and IL-2,
with or without 5-fluorouracil. The in-
terval between the last therapy course
and enrollment in this study was at
least 3 months. All patients progressed
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Table 2. Absolute numbers of peptide-reactive T cells in the periphery (per 150,000 cells pre-/postvaccination).
Patient TYMS IGF-BP3 RGS-5 VEGF MMP7 CA IX PRUNE TIF1 NY-ESO Pool Ca Pool Eb DTH
MR-1 51/41c 43/32 d–/16 45/85 14/43e –/24 nd/nd 22/nd 81/112 –/15 12/51 +
MR-2 12/45 64/183 49/135 22/124 48/162 –/65 –/66 50/82 24/173 19/107 39/157 ++
MR-4 23/70 38/107 123/40 80/70 76/157 –/29 105/58 nd/73 40/63 66/71 99/97 +
MR-5 –/17 –/60 19/41 32/41 24/42 –/23 nd/nd –/37 –/64 –/64 13/73 +
MR-6f 12/27 30/48 49/18 –/– –/– –/– –/– –/– –/– –/– –/11 –
MR-7f –/– –/– –/50 –/13 –/46 –/– nd/nd 13/55 –/– 22/126 15/46 +
MR-9f –/– –/– –/– –/– –/28 –/– –/– –/– –/12 15/31 39/37 (+)
MR-10 60/20 64/13 82/49 77/33 56/45 32/– 32/19 89/57 69/29 69/54 123/155 (+)
MR-11 –/39 99/37 –/43 51/nd –/– 42/– –/– 29/46 142/255 52/107 128/210 +
MR-13 28/46 71/80 40/62 61/32 111/17 –/– –/– 40/101 80/32 41/74 157/125 ++
MR-14 23/36 76/141 39/49 –/126 –/64 28/33 –/14 52/67 16/44 –/63 12/70 ++
MR-15 11/– –/28 –/15 –/59 15/25 –/– –/25 4/53 14/31 –/14 –/67 +
DTH, delayed-type hypersensitivity reaction; nd, not determined (not enough cells).
aPool C contains the peptides for ORMDL3, AHNAK-rel, BTG1, PIG10, LENG4, CP and PRAME.
bPool E contains the peptides for TIF1, CLIC1, ELAC2 and TMP1.
cThe values represent absolute numbers of spots for pre- and postvaccination (pre/post) responses. These values are given after
subtraction of background responses (that is, without peptide or with irrelevant Bcr/Abl peptide). The highest postvaccination response is
given irrespective of the time point postvaccination (that is, at 6, 14, 22 or 36 wks).
dNo values mean no reactivity (≤10 spots above background, which corresponds to a frequency of ≤1 = 1.5 × 104 IFN-γ–secreting peptide-
specific T cells).
eValues representing a greater than two-fold increase in reactivity against the peptides post- versus prevaccination are indicated in bold.
With the larger peptide pools, a reactivity of ≥40 spots above background was considered positive.
fShort protocol of vaccination starting with the middle dose of 107 vaccine cells. DTH reactivity: –, negative; (+), weak; +, positive; ++,
positive (>2 cm redness and/or induration).
during the study, except for patients
MR-11 and MR-15.
Routine blood parameters and common
side effects were described previously
(10). Peripheral blood leukocyte popula-
tions were not changed significantly dur-
ing vaccination (Supplementary Figure
S2). Patients MR-5, MR-11 and MR-14
showed transient increase of eosinophils
(>500 cells/μL blood). Most patients
(67%) showed transiently increased neu-
trophil granulocyte to lymphocyte ratios
during vaccination (ratio >4). Two pa-
tients demonstrated extremely high ratios
at the end of their vaccination courses, at
time of progression (MR-7, MR-10; ratio
>21; data not shown).
High Rates of Immune Response
Occurred after Vaccination
PBMCs were obtained throughout vac-
cination for IFN-γ ELISPOT analyses to
compare lymphocyte responses to a vari-
ety of peptide antigens before and after
vaccination (see Supplementary Fig -
ure S1). Three patients (MR-3, MR-8 and
MR-12) were not included because of
early progression and removal from
study.
In our previous trial report, we
demonstrated that all patients responded
before vaccination to pooled control pep-
tides from cytomegalovirus, Epstein-Barr
virus and influenza virus (CEF peptides)
and to vaccine cell lysate, with increases
in responses to tumor cell lysate noted in
66% of patients after vaccination (10).
Here, additional ELISPOT responses
after vaccination were analyzed by using
surrogate peptides derived from numer-
ous TAAs that are overexpressed in RCC
or other tumors. Selected TAAs were
tested for prevalence and expression by
using microarray analysis of 32 mRCC
tumors, parental RCC-26 cells and vac-
cine cells (Supplementary Table S2).
Nearly all selected TAAs were expressed
in the majority of tumor samples. Two
TAAs (carbonic anhydrase IX [CAIX]
and PRUNE2) were present in metastatic
lesions but were not detected in parental
RCC-26 or vaccine cells. Matrix metallo-
proteinase 7 (MMP7) was not detected in
the vaccine and NY-ESO1 was missing
throughout. Several HLA-A2–restricted
peptides (transcriptional intermediary
factor 1 [TIF1], chloride intracellular chan-
nel protein 1 [CLIC1], elaC homolog-2,
putative prostate cancer susceptibility
protein 2 or heredity prostate cancer pro-
tein 2 [ELAC2], tropomyosin 1 [TPM1],
ORM1-like protein 3 [ORMDL3],
AHNAK-related protein [AHNAK-rel], 
B cell translocation gene 1 protein
[BTG1], p53-induced gene 10 protein
[PIG10] and LENG4) were eluted from
RCC-26 cells, identifying additional
TAAs. All peptides selected from these
TAAs carried anchor residues for 
HLA-A*02:01, matching the HLA-A2 al-
lotype of patients (see supplementary
Material and Methods section ELISPOT).
The summary of ELISPOT results for
12 patients is shown with values before
treatment juxtaposed to the strongest re-
corded responses detected at any time
after vaccination (Table 2). The delayed-
type of hypersensitivity reactions (DTH)
are also indicated here. All patients ex-
cept MR-6 developed DTH responses
after a challenge with 2.5 × 106 vaccine
cells, applied intradermally in the alter-
nate inguinal region at wks 6, 14 and 22.
In previous studies, we demonstrated
patient ELISPOT responses to peptides
derived from survivin, cyclin D1,
adipophilin, c-Met and vimentin (10).
Here, our analyses were extended to in-
clude thymidylate synthetase (TYMS),
insulin-like growth factor binding pro-
tein 3 (IGF-BP3), PRUNE2, transcrip-
tional intermediary factor 1 (TIF1), regu-
lator of G protein signalling 5 (RGS5),
VEGF, MMP7, CAIX and NY-ESO1, in
addition to two pools, including 10 addi-
tional peptides. Interestingly, 100% of the
patients reacted to at least one peptide in
the entire set of analyzed epitopes.
Greater than two-fold increases in reac-
tivity to at least two peptides were de-
tected in 75% of patients after vaccina-
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Table 3. Peptide reactivity, immune response rate and clinical response.
Peptide reactivity
(number of tested peptides)
Patient ID Prevaccination Postvaccination TTP (wks) Survival (wks)
MR-1 a10/15b 7/13 (2)c 7 31
MR-2 12/16 15/17 (11) 23 79
MR-4 13/14 15/17 (7) 35 68
MR-5d 3/14 15/15 (11) 7 76
MR-6d 8/16 3/17 (1) 6 18
MR-7d 2/16 5/15 (5) 28 84
MR-9 3/18 4/17 (1) 39 79
MR-10 16/19 13/19 (0) 23 55
MR-11 7/17 7/15 (3) SD (7)e 17
MR-13 13/18 13/18 (4) 33 104 (alive)
MR-14 9/19 17/19 (9) 35 107
MR-15 6/19 15/19 (8) SD (131)e 151 (alive)
Immune response rate (%) 100f 100 (75)f
Clinical response (wks) 25.5g 77.5g
TTP, time to progression; SD, stable disease.
aNumbers of peptides to which reactivity was observed (>10 spots above background).
bNumbers of peptides tested (survivin, cyclin D1, adipophilin, c-MET, vimentin, PRUNE2, VEGF,
NY-ESO, MMP7, TYMS, IGF-BP3, RGS-5, CA IX, CP, TIF-1, ORMDL3, CLIC1, ELAC2 and PIG-10).
cNumbers of peptides (in bold) to which a greater-than-two-fold increase after versus
before vaccination was detectable.
dShort protocol of vaccination starting with the middle dose of 107 vaccine cells.
eSD (7) and SD (131) indicate stable disease at wks 7 and 131, respectively.
fPatients reacting to more than one peptide in %.
gMedian PD and median survival in weeks.
tion (Table 3). The time course of re-
sponses varied as illustrated for three pa-
tients (Supplementary Figure S3). Faster
responses in MR-13 and MR-14 may be
due to prior multi-peptide vaccination
given more than 4 months before study
entry. MR-2 showed a pattern representa-
tive of most patients, whereby immune
responses increased later in treatment.
Figure 1A shows the total number of
IFN-γ– secreting T cells, given as total
number of spots for all tested antigens.
This result demonstrates the magnitude
of vaccine-induced immune responses.
In general, patients with a higher total
number of spots showed a longer sur-
vival, and the same was observed for pa-
tients recognizing higher numbers of
peptides (Figure 1B). The survival proba-
bility for patients reacting to 0–2 versus
≥3 peptides demonstrated a trend for in-
creased length of survival in patients
achieving broader immune responses
(Figure 1C).
Frequencies of Tregs Decreased after
Vaccination
Immune suppression in cancer pa-
tients is often discussed to result from
higher numbers of Tregs or MDSCs. For
this reason, we analyzed frequencies of
CD4+CD25highCD127low/negativeFoxp3+CD3
9+ cells in patient PBMCs. Supplemen-
tary Figure S4 shows the gating strategy
for patient MR-1. In general, frequency
of Tregs before vaccination (median 2.60,
minimum 0.93, maximum 3.56) was simi-
lar to that in healthy controls (median
2.71). A decrease of Tregs was observed
after vaccination (p = 0.065, Supplemen-
tary Table S3). This change with respect
to vaccination could even be demon-
strated with absolute numbers of Tregs
(p = 0.034, Figure 2A). To quantify nTregs
more precisely, we used a real-time PCR-
based methylation assay using methyla-
tion- and demethylation-specific primers.
Baseline levels of stable Foxp3-expressing
nTregs in the patient cohort did not dif-
fer from healthy controls. Interestingly,
significant decreases of nTregs (p = 0.012)
were detected in patients after vaccina-
tion, as illustrated in Figure 2B. A com-
bined analysis of total numbers of re-
sponding T cells before and after
vaccination (Figure 3A) and absolute
numbers of Tregs before and after vacci-
nation (Figure 3B) suggests a reciprocal
relationship, as might be expected, but
this result did not reach significance
owing to the small number of patients
(Figure 3C; p = 0.243, r = –0.365).
Patients with Fewer MDSCs Trended to
Longer Survival
MDSCs represent a second cell popu-
lation with suppressive function, which
was also described in RCC patients (15).
These cells were immunophenotyped by
using antibodies specific for CD3, CD19,
CD14, CD15, CD11b, CD33, HLA-DR
and CD124. Supplementary Figure S5
shows the gating strategy for different
MDSC cell subpopulations for patient
MR-15, as a representative example.
Five subpopulations were detected in
RCC patients and healthy donors:
MDSC1 (CD14+ CD124+), MDSC2
(CD15+ CD124+), MDSC3 (Lin– HLA-
DR–, CD33+, SSChigh), MDSC4 (SSCim
CD14+ HLA-DR–) and MDSC5 (CD14–
CD15+ CD11b+). Results for all patients
are given in Supplementary Table S4.
Slightly increased frequencies of
MDSC4 and MDSC5 were observed in
58% of patients compared with healthy
donors. Significant increases or de-
creases in any of the five MDSC sub-
populations were not observed before
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Figure 1. Correlation of immune response
to survival time. (A) Total spot number is
shown for each patient (n = 12) (y axis) to
demonstrate the magnitude of the vac-
cine-induced immune response in correla-
tion to survival (x axis). (B) The number of
peptides (y axis) to which each patient re-
sponded is shown in relation to survival 
(x axis). (C) Survival probability of the pa-
tients with immune responses to 0–2 pep-
tides (dashed line) and immune responses
to ≥3 peptides (solid line). p = 0.066; log-
rank test.
Figure 2. Decreased frequencies of nTregs
during vaccination. (A) Absolute number
of CD4+CD25highCD127low/negativeFoxP3+
CD39+ Tregs per μL blood measured by
flow cytometry before and after vaccina-
tion for each patient (n = 12). The median
is indicated. p = 0.034; Wilcoxon signed-
rank test. (B) The nTregs were quantified
with a real-time PCR-based methylation
assay with methylation- and demethyla-
tion-specific primers. The y axis shows the
percent of nTregs, and the x axis shows
three different time points of the study pro-
tocol. Post-2 is the same time point as the
postvaccination time point in (A). The de-
crease of nTregs is statistically significant
with p < 0.05 (Wilcoxon signed rank test).
and after vaccination, even when calcu-
lated for absolute numbers. However,
there was a trend for better immune re-
sponses in patients with lower frequen-
cies of MDSC4 and MDSC5. Figure 4 in-
dicates a slightly higher survival
probability for patients with lower fre-
quencies of MDSC4 (p = 0.091), al-
though these differences did not reach
significance because of the small num-
ber of  patients.
Effector T Cells Displayed Mixed
TH1/TH2-Like Cytokine Profiles
Cytokine profiles also provide useful
information about the effects of im-
munotherapeutic vaccination. There-
fore, we analyzed the general cytokine
profile in PBMC responses to vaccine
cells. In unstimulated controls, a pre-
dominant secretion of IL-10 and the
proinflammatory cytokines IL-1β, IL-6,
IL-8 and TNF-α was found, whereas
there was no or only low detection of
IL-2, IL-4, IL-5 and IFN-γ (Supplemen-
tary Table S5). After stimulation with
vaccine cells, much more IFN-γ, IL-2,
IL-4 and IL-5 were measured, which in-
creased further after a second restimu-
lation. Also, IL-10 increased after a sec-
ond stimulation. In contrast, secretion
of IL-1β, IL-6, IL-8 and TNF-α de-
creased after stimulation. This result
can be interpreted as a mixed T helper
1/T helper 2 (TH1/TH2)-like profile, re-
flecting decreases of proinflammatory
cytokines after in vitro restimulation
with vaccine cells.
Challenge Site Infiltrating
Lymphocytes Produced IL-10 and
IFN-γ–Dependent Chemokines
Cytokines secreted by skin-infiltrating
lymphocytes were analyzed in skin biop-
sies taken 48 h after an intradermal (i.d.)
vaccine challenge at wks 6, 14 and 22.
Small pieces of biopsies were cultured
for 10–19 d, depending on the number of
outgrowing cells. The composition of in-
filtrating cell populations differed from
biopsy to biopsy and depended on the
cultivation period. After 10 d, up to 95%
of infiltrating cells were T cells and NK
cells with residual B cells, eosinophils,
macrophages and monocytes (data not
shown).
Substantial differences were noted in
the cytokine/chemokine profiles of the
skin-infiltrating lymphocytes taken at
different times (Supplementary Table S6).
IL-5 and IL-13 were greatest in the first
biopsy at 6 wks and declined substan-
tially thereafter. Most factors were at a
maximum in cells isolated from wk 14
biopsies, after patients had received eight
vaccine doses. IL-10 increased through-
out vaccination for most patients, in ad-
dition to three other factors (RANTES,
IP-10 and MIG), all of which are induced
by IFN-γ.
Multiple Serum Cytokines Increased
During Vaccination
Supplementary Table S7 shows serum
cytokine levels. All cytokines increased
slightly during vaccination, however,
sometimes only transiently. Small in-
creases in IFN-γ were observed in 64% of
patients, with maximum levels reaching
>20 pg/mL for several patients (MR-11,
MR-13 and MR-15 [data not shown]).
These same patients also showed in-
creases of IL-10. Enhanced IL12p70 secre-
tion was only detected in patients who
had longer survival times (MR-13, MR-14
and MR-15). IL-5 but not IL-4 was
slightly enhanced in most patients,
whereas IL-17 was only detected in one
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Figure 3. Reciprocal correlation between vaccine-induced immune response and Treg
numbers. (A) Total number of spots before and after vaccination for each patient (IFN-γ
ELISPOT). (B) Absolute number of CD4+CD25highCD127low/–Foxp3+CD39+ Tregs before and
after vaccination for each patient (flow cytometry). (C) Fold-change of T-cell response
(total spot number) versus fold-change of Treg number (absolute number of
CD4+CD25highCD127low/–Foxp3+CD39+ Tregs). p = 0.243; correlation coefficient r = –0.365,
Spearman rank correlation.
patient (MR-11). Increases in IL-5 were
not associated with higher numbers of
eosinophils (Supplementary Figure S6).
Between 40% and 60% of patients
showed enhanced levels of IL-6, IL-8 and
C-reactive protein, which have been re-
ported to be elevated in patients with ad-
vanced disease. Changes were not de-
tected in levels of VEGF-C, VEGF-D and
PGE2, whereas VEGF-A and TGF-β1 de-
creased slightly over time (Supplemen-
tary Table S8).
DISCUSSION
Extensive preclinical studies demon-
strated that RCC-26 displays strong im-
munogenic potential that was enhanced
by gene modification to allow the RCC-
26 vaccine cells to express surface CD80
and to secrete IL-2 (11). On the basis of
its improved stimulatory capacity, a
phase I vaccine trial was performed in
HLA-A2–matched patients with modi-
fied RCC-26 cells (10).
The majority of patients had multiple
metastases at two or more sites at enroll-
ment, and 42% of patients had poor
prognosis scores (10,14), revealing their
advanced state of disease. Nevertheless,
50% of patients achieved a state of stable
disease ranging from 23 to 131 wks,
with a median time to progression of
5.3 months and median tumor-specific
survival time of 15.6 months (10). Studies
of larger numbers of patients with simi-
lar advanced disease showed progres-
sion-free survival of 5.5 months with the
angiogenesis inhibitor sorafenib (16) and
5.0 months with IFN-α (17); however, the
side effects of these therapies were much
greater.
All patients but one showed DTH re-
actions that increased in magnitude over
time, indicating strong induction or reac-
tivation of T-cell responses in vivo
through vaccination. To better under-
stand the basis of vaccine-induced im-
mune responses that may have con-
tributed to stable disease, we analyzed
numerous immune parameters in patient
blood lymphocytes, serum and vaccine-
site biopsy samples. Among the numer-
ous parameters that were assessed, the
results of antigen-specific T-cell re-
sponses and the frequencies of Tregs and
MDSCs were most informative.
IFN-γ–secreting cells were measured
after ex vivo stimulation with numerous
new RCC-associated antigens. Here, a
large panel of surrogate peptides, repre-
senting epitopes derived from TAAs
known to be overexpressed in RCC, were
used in addition to several peptides
eluted from RCC-26 cells. Peripheral
blood lymphocytes (PBL) of all but one
patient responded to more than one pep-
tide, and the vaccine- induced immune
response rate was 75%. Some patients re-
acted to epitopes (for example, PRUNE2
and CAIX) that were not expressed by
vaccine cells, demonstrating the occur-
rence of epitope spreading. Over the full
survival time range of 160 wks, it was
apparent that a higher magnitude of 
T-cell response was seen in most patients
who survived longer. Likewise, complex
responses to several different peptides
were more common in patients with
longer survival. Thus, three of four pa-
tients responding to fewer than three
peptides survived <15 months; their total
number of T cells responding to the pep-
tide panel was <200. In contrast, seven of
eight patients responding to three or
more peptides survived beyond 15
months and had total T-cell responses
ranging from 200 to 1,138 spots.
Poor clinical outcome in many cancer
patients is associated with higher num-
bers of Tregs or MDSCs. Thus, elevated
Treg numbers in peripheral blood, tu-
mors or lymph nodes were associated
with poor prognosis (18,19). In some
cases, decreased numbers of Tregs were
observed after sunitinib treatment, and
this result correlated with improved
overall survival (20,21). Treg depletion
may support enhanced vaccine-induced
antitumor immunity (22). In our cohort,
baseline levels of stable Foxp3-express-
ing nTregs in patients did not differ from
healthy controls, as reported for a related
vaccine study (23). In contrast, significant
decreases of nTregs (p = 0.012) were de-
tected in this patient cohort after vaccina-
tion, and to some degree, these decreases
were matched with increases in antigen-
specific T-cell responses. Thus, this IL-2–
secreting vaccine did not cause higher
frequencies of nTregs, as seen with sys-
temic IL-2 treatment in melanoma and
RCC (24,25) or during treatment of
mRCC patients with dendritic cells and
low-dose IL-2 (26). Our vaccine strategy
appears to have a favorable profile with
respect to impact on Treg frequencies.
The mechanism underlying this effect is
unknown but may be related to the effect
of vaccination on the cytokine network.
Furthermore, the IL-2 from our vaccine is
unlikely to have systemic effects, since
the cells are applied intradermally.
MDSCs can also interfere with im-
mune responses by several different
mechanisms (15,27–32), and increased
numbers of MDSCs have been correlated
with cancer stage and metastatic spread
(33). MDSCs were reported in RCC (15),
and enhanced antitumor immunity was
obtained by reversing MDSC-mediated
immune suppression after treatment
with sunitinib or all-trans-retinoic acid
(34,35). In our patient cohort, increased
levels of MDSC4 and MDSC5 were
found in 58% of patients compared with
healthy donors. These values did not sig-
nificantly change before and after vacci-
nation. A trend for better survival was
seen for patients who had lower frequen-
cies of the MDSC4 subset.
1 5 0 6 |  P O H L A  E T  A L .  |  M O L  M E D  1 8 : 1 4 9 9 - 1 5 0 8 ,  2 0 1 2
I M M U N E  M O N I T O R I N G  O F  A  K I D N E Y  C A N C E R  V A C C I N E  S T U D Y
Figure 4. Survival probability of patients
with high versus low frequencies of
MDSC4. Survival probability of the patients
(n = 12) with MDSC4 in %/lymphocytes <
median (solid line) and MDSC4 in 
%/lymphocytes > median (dashed line).
Median = 12.13%; p = 0.091; log-rank test.
Cytokine profiles may also provide
useful information for understanding
clinical effects of immunotherapy. The
presence of elevated systemic levels of
proinflammatory cytokines may indi-
cate unfavorable clinical outcomes in
patients with advanced solid tumors
(36). The cytokine balance gives an indi-
cation of the overall inflammatory mi-
lieu. Kyte et al. (37) reported that mixed
TH1/TH2 cytokine patterns in vaccinated
melanoma patients, even at the clonal 
T-cell level, were associated with long-
term survival.
In this cohort, 64% of patients showed
increases in serum IFN-γ during vaccina-
tion, but the same patients also demon-
strated a TH2-like profile. In general, as-
sociations of particular serum cytokine
profiles with immune response rates or
survival times were not obvious, with
the exception that IL-12p70 was only de-
tected in patients who survived longer.
IL-12 is known to activate TH1 cells and
NK cells, and it was described by others
that higher levels of IL-12p70 were asso-
ciated with better survival in mRCC (38).
The mechanisms by which vaccination
led to increases in this cytokine are un-
known, but it is possible that T cells pro-
ducing IFN-γ led to IL-12p70 production
by dendritic cells.
Four TH2 cytokines were prominent in
cohort samples. The slightly enhanced
IL-10 secretion, as measured both in
serum and in skin-infiltrating lympho-
cytes during vaccination, did not neces-
sarily mean immune suppression. The
role of IL-10 in immune response against
cancer is still controversial. One report
suggests that IL-10 may favor immune-
mediated rejection of cancer (39). Persis-
tent, moderate threshold levels of IL-10
seem to be necessary for inhibition of
tumor growth by activated effector TH1
cells (40).
Chemokines play a major role in
leukocyte trafficking to sites of inflam-
mation. An increase of chemokines in-
duced by IFN-γ (RANTES, IP-10 and
MIG) was observed in skin-infiltrating
cells after stimulation with vaccine cells
in vitro. IP-10 plays an important role in
DTH reactivity and is chemotactic for
T cells, NK cells, dendritic cells, macro-
phages and monocytes. Schwaab et al.
(41) observed a treatment-related induc-
tion of IP-10 and a relationship between
outcome and pretreatment serum IP-10
levels (41). IP-10 expression in RCC tu-
mors has been described as a predictor of
good outcome and was shown to be in-
duced by IL-2 and implicated as a com-
ponent of TH1 responses (42). MIG is a
chemoattractant for T cells, and RANTES
is chemotactic for T cells, monocytes and
eosinophils and plays a role in recruiting
these cells into inflamed tissues. Thus,
induction of these factors may reflect a
positive impact of vaccination on im-
mune responses in patients showing this
response profile.
In general, the complexity of cytokine
networks makes it difficult to determine
the relationships between immune
 response rates, systemic cytokine/
chemokine levels and clinical outcome,
particularly in a small cohort. It will be
necessary to analyze larger patient co-
horts to understand how these complex
networks regulate immune responses
during vaccination.
CONCLUSION
In summary, these extensive immune
monitoring studies demonstrate that
most patients in this trial acquired in-
creased T-cell reactivity during vaccina-
tion to several epitopes derived from
shared TAAs and vaccine-eluted pep-
tides. Despite its allogeneic nature, this
generic vaccine induced TAA-associated
T-cell responses that may elicit signifi-
cant immune attack of autologous
tumor cells in better clinical settings. In
future combination therapies or in adju-
vant therapies for RCC patients with
minimal residual disease, preanalysis of
patients for general immune response
capacity and prevalence of suppressor
cell populations might guide the better
use of vaccines. Only patients with an
overall good immune response capacity
and normal numbers of suppressor 
cells may benefit from tumor vaccine
approaches.
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